Abstract 231P
Background
Anal cancer is a rare cancer, over the last decade anal cancer incidence have increased significantly. Previous studies evaluated only squamous cell carcinoma type, However, the studies that looked at all subtypes, showed some contradictions regarding survival outcomes among different genders. This study aims to investigate gender disparities' impact on anal cancer survival in the three stages to give more accurate results.
Methods
17 registries from the SEER database were used during 2000-2020. Patients who took the standard chemoradiation therapy were grouped into 2 main groups based on their sex (male, female), In addition to their stages (localized, regional, distant), according to Seer combined summary stage 2000 (2004-2017). SPSS 27 was used for statistical analysis, the Kaplan-Meier curve, and the long-rank test for survival analysis.
Results
8113 Patients, 65.8% of were female and 34.2% were male who took the standard therapy have an overall 5-year age-standardized relative survival rate of 58.3%. The distribution across stages was 67.4% localized, 14.6% regional, and 18% distant. In localized stage, survival rates were 70.1%, 59.0% for female and male respectively (p value <. 001). While regional stage rates were 55.3%, 39.2% for female and male respectively (p-value <.001). Finally, in the distant stage survival rate for females is 41.0% whereas for males is 24.1% (p-value <.001).
Conclusions
Our study shows a critical gender disparity in anal cancer survival across all stages, with males having lower rates especially in late stages. Although incidence rates are higher in females than males, however, survival rates of men are significantly lower. This finding demands future studies to optimize treatment strategies and improve outcomes, particularly for men.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.